HUTCHMED

On July 4, 2024, Hong Kong Investor Relations Association (HKIRA) announced the winners of its 10th Investor Relations Awards 2024. HUTCHMED received four awards in the categories of “Best IR by Chairman/CEO”, “Best IR Company”, “Best IR Team” and “Best ESG (E)”. https://lnkd.in/gz67Xp6E Despite the volatile and challenging global economy and market condition, HUTCHMED team remains steadfast in executing our global vision of bringing innovative medicines to patients the world over. Over the last 12 months, we held over 700 meetings with investors through roadshows and conferences throughout China and around the world. There are now 34 sell-side analysts covering HUTCHMED’s stock. Our team will continue to work hard to increase transparency of disclosure, maintain equitable distribution of information, as well as provide prompt and accurate response to queries from investors and other stakeholders.

We are happy to share that the New Drug Application for tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma has been accepted for review and granted Priority Review by the China National Medical Products Administration (NMPA). https://lnkd.in/gFYzVcvJ

We will host in-person presentation and online webinar on Tuesday, July 9, 2024 to share insights into our R&D strategy and vision. Our senior management team will provide updates on certain programs within HUTCHMED’s extensive and innovative pipeline. This will include updates on the Phase III ESLIM‑01 and Phase II/III ESLIM‑02 studies of our Syk inhibitor sovleplenib in ITP and wAIHA respectively; the surufatinib Phase II/III study for metastatic pancreatic ductal adenocarcinoma; and the Phase III RAPHAEL study of our IDH1/2 inhibitor HMPL-306 in acute myeloid leukemia. https://lnkd.in/dVdSwS-F

We are pleased to share that our partner Takeda has received European Commission approval for a new treatment for adults with previously treated metastatic colorectal cancer. It is the first product from our research and discovery engine to be approved in Europe. #ColorectalCancer #mCRC Learn More: https://lnkd.in/gUr7cMxe

We are happy to share that results from ESLIM-01, HUTCHMED’s Phase III trial of sovleplenib in adult patients with primary immune thrombocytopenia (ITP) in China, were published in The Lancet Haematology. Additional details and subgroup results of the study were also presented on June 14 at the European Hematology Association (EHA) 2024 Hybrid Congress as an oral and two poster presentations. https://lnkd.in/gU6YNEtq

We have initiated a Phase I clinical trial of our menin inhibitor HMPL-506 in patients with hematological malignancies in China. HMPL-506 is a novel, investigational, selective small molecule inhibitor for oral administration targeting the menin protein. https://lnkd.in/g5TvjkxY

We are happy to share that results from the FRUTIGA Phase III trial of fruquintinib in second-line gastric cancer in China have been published in Nature Medicine. Updated efficacy data in key subgroups and data on quality of life (QoL) within this publication were also presented on June 1 at the American Society of Clinical Oncology 2024 Annual Meeting #ASCO24. https://lnkd.in/gdG9Cra3

New and updated data of compounds discovered by HUTCHMED will be presented at the upcoming American Society of Clinical Oncology #ASCO24 Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL and online. https://lnkd.in/gz9XBdVv Results will be presented from the registration Phase II study of fruquintinib combined with sintilimab for the treatment of advanced endometrial cancer, which supported the New Drug Application (NDA) filed in China.  In addition, further updated efficacy data and quality of life data in key subgroups of fruquintinib's Phase III gastric cancer study FRUTIGA, as well as further data from the FRESCO and FRESCO-2 Phase III colorectal cancer studies, the study of surufatinib combinations in small cell lung cancer, and initial clinical data for the ERK1/2 inhibitor HMPL-295 will be presented.

Topline and subgroup results from the ESLIM‑01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association #EHA24 Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online. https://lnkd.in/gphtawRw

We are pleased to share that we have initiated the RAPHAEL registrational Phase III trial of HMPL-306 in patients with mutated IDH1/2 relapsed/refractory acute myeloid leukemia in China. https://lnkd.in/gKmqqcyB